Repare Therapeutics Inc. RPTX

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
55/100
Moderate

Ranked against 712 peers in Biotechnology

About Repare Therapeutics Inc.

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective … Full RPTX analysis →

Key strengths

  • Strong Liquidity Buffer Liquidity position is strong (score 0.66), providing operational cushion.
  • Operating Expense Control OpEx growth is controlled (score 0.66), demonstrating operating leverage.

Key risks

  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.13), suggesting weak customer stickiness.
  • Elevated Debt Risk Debt serviceability is weak (score 0.00), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
42
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where RPTX ranks in Biotechnology

Repare Therapeutics Inc. ranks #172 of 713 scored companies in Biotechnology by moat score — the top 24%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
168 ARCA biopharma Inc ORKA 55/100 Moderate
169 Evaxion Biotech A/S EVAX 55/100 Moderate
170 Geron Corporation GERN 55/100 Moderate
171 Oric Pharmaceuticals, Inc. ORIC 55/100 Moderate
172 Repare Therapeutics Inc. RPTX 55/100 Moderate
173 Madrigal Pharmaceuticals, Inc. MDGL 55/100 Moderate
174 MiNK Therapeutics, Inc. INKT 55/100 Moderate
175 Arcutis Biotherapeutics, Inc. ARQT 55/100 Moderate
176 Immunic, Inc. IMUX 55/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How RPTX scores on the Corporate Default defenses

Pricing Power

Score 42 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 73 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 45 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 43 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 66 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 72 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding RPTX's moat

What is Repare Therapeutics Inc.'s moat score?

Repare Therapeutics Inc. (RPTX) scores 55 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #172 of 713 scored companies in Biotechnology, the top 24%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Cost Advantage (73/100) and its weakest is Pricing Power (42/100).

How does Repare Therapeutics Inc. compare with other Biotechnology companies?

Repare Therapeutics Inc. ranks #172 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Oric Pharmaceuticals, Inc. (ORIC) at 55 just above it and Madrigal Pharmaceuticals, Inc. (MDGL) at 55 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Repare Therapeutics Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Repare Therapeutics Inc.?

The Corporate Default template measures 6 defenses, and RPTX scores: Pricing Power (42), Cost Advantage (73), Customer Stickiness (45), Capital Efficiency (43), Resilience (66), Scale & Market Position (72). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000